Treatment consistency emerges as a critical factor in managing the most challenging breast cancer cases, where tumor invasion extends beyond the breast tissue itself. Analysis of over 130,000 European patients reveals significant disparities in how oncologists approach these complex diagnoses, with implications for survival rates across the continent.
The EUSOMA database analysis identified 3,404 patients with locally advanced disease between 2013-2022, representing 2.6% of all cases. Inflammatory breast cancer patients received more intensive treatment protocols, with 77% receiving pre-surgical chemotherapy compared to just 33% of other advanced cases. Biological targeted therapies reached 88% of inflammatory cases versus 67% of non-inflammatory advanced tumors. Radiation therapy followed similar patterns, administered to 80% versus 61% respectively.
This treatment intensity gap appears clinically puzzling given that survival outcomes showed no statistical difference between inflammatory and non-inflammatory advanced cases when controlling for other factors. Age under 70, specific molecular subtypes (luminal A and HER-2 positive), complete surgical resection, radiation therapy, and systemic treatment all independently predicted better survival. Local recurrence rates dropped significantly with radiation or hormone therapy.
The findings suggest European oncologists may be over-treating inflammatory cases while potentially under-treating other advanced presentations. With one-quarter of these patients presenting with metastatic disease, standardizing aggressive multimodal approaches could improve outcomes. The data challenges assumptions about inflammatory breast cancer requiring uniquely intensive protocols, pointing instead toward more consistent application of comprehensive treatment regardless of specific advanced cancer subtype.